# DATELINE:

Washington, D.C.

November 8, 2017

Inaugural Innovations in Regulatory Science Awards Gala to honor FDA’s Janet Woodcock and Janssen R&D’s Patrick Ryan

The Director of FDA’s Center for Drug Evaluation and Research and an industry epidemiology analyst pioneering big data for public safety are the first two awardees to be honored at a December 5th event celebrating advances in regulatory science.

[The Reagan-Udall Foundation for the FDA’s](http://reaganudall.org/) Gala Awards committee announced today that Dr. Janet Woodcock was selected from a field of nominees to win the Leadership Award and Dr. Patrick Ryan won the Healthcare Innovation Award.

The congressionally mandated nonprofit charged with helping FDA modernize regulatory science will present the Leadership and Innovation Awards at its first-ever, [Innovations in Regulatory Science Awards Gala](http://reaganudall.org/innovations-regulatory-science-awards-gala) December 5th in Washington, D.C.

“Behind every breakthrough therapy approved by the FDA are dedicated regulatory scientists assuring safety and efficacy,” said June Wasser, Executive Director of the Reagan-Udall Foundation for the FDA. “The Foundation hopes the Awards Gala will raise awareness about the importance of these champions of public health.”

Dr. Woodcock’s 30 years at the FDA has contributed to advances in pharmacogenomics and the regulation of novel therapies arising from biotechnology, as well as less headline-grabbing initiatives to ensure pharmaceutical risk management, data standardization and drug safety.

“She has dedicated her career to a future where the science of safety and efficacy is as advanced as the R&D it regulates,” said Dr. Garry Neil, member of the Reagan-Udall Foundation Board of Directors and chair of the awards committee. “That’s why we’re honored to present the inaugural Leadership Award to Dr. Woodcock.”

The recipient of the Healthcare Innovation award, Dr. Ryan, is the Sr. Director and Head of Epidemiology Analytics at Janssen Research and Development. He helped develop data collection alternatives to traditional randomized trials through the Observational Health Data Sciences and Informatics network (OHDSI).

“This award specifically honors a person or organization advancing regulatory science through novel initiatives,” said Neil. “Dr. Ryan’s work in real-world data, addressing population health and medical product safety, has set a new bar for the field and complements the Foundation’s Innovation in Medical Evidence Development and Surveillance [(IMEDS)](http://reaganudall.org/innovation-medical-evidence-development-and-surveillance) Program.”

Both honorees will accept their awards at the Foundation’s December gala, held from 6:00pm – 9:00pm, at the Kaiser Permanente Center for Total Health. FDA Commissioner Dr. Scott Gottlieb will address attendees. Tickets are available [online](http://reaganudall.org/innovations-regulatory-science-awards-gala) and proceeds from the event support the non-profit Foundation’s mission. The presenting sponsor of the gala is Deloitte and other contributing sponsors include the Pharmaceutical Research and Manufacturers of America (PhRMA), Johnson & Johnson, Eli Lilly and Company, Greenleaf Health, the Biotechnology Innovation Organization (BIO), Aevi Genomic Medicine, Flagship Pioneering, the American Society of Clinical Oncology, Susan G. Komen, Alston & Bird and Kaiser Permanente.

## About the Reagan-Udall Foundation for the FDA

 The Reagan-Udall Foundation for the FDA is an independent, nonprofit corporation created by Congress to advance the mission of the Food and Drug Administration. It does not participate in regulatory matters or offer advice to FDA on policy.

###

## Media Contact Information (not for publication)

###  For questions about the Innovations in Regulatory Science Awards Gala or the Reagan-Udall Foundation for the FDA contact:



tbruce@reaganudall.org